IL191911D0 - Vaccine comprising streptococcus pneumoniae capsular polyaccharide conjugates - Google Patents

Vaccine comprising streptococcus pneumoniae capsular polyaccharide conjugates

Info

Publication number
IL191911D0
IL191911D0 IL19191108A IL19191108A IL191911D0 IL 191911 D0 IL191911 D0 IL 191911D0 IL 19191108 A IL19191108 A IL 19191108A IL 19191108 A IL19191108 A IL 19191108A IL 191911 D0 IL191911 D0 IL 191911D0
Authority
IL
Israel
Prior art keywords
polyaccharide
conjugates
vaccine
streptococcus pneumoniae
pneumoniae capsular
Prior art date
Application number
IL19191108A
Other versions
IL191911A (en
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to GB0526232A priority Critical patent/GB0526232D0/en
Priority to GBGB0607088.2A priority patent/GB0607088D0/en
Priority to GB0607087A priority patent/GB0607087D0/en
Priority to GB0609902A priority patent/GB0609902D0/en
Priority to GBGB0620336.8A priority patent/GB0620336D0/en
Priority to GB0620337A priority patent/GB0620337D0/en
Priority to GB0620816A priority patent/GB0620816D0/en
Priority to GB0620815A priority patent/GB0620815D0/en
Priority to PCT/GB2006/004634 priority patent/WO2007068907A2/en
Priority to PCT/EP2006/069977 priority patent/WO2007071710A2/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL191911D0 publication Critical patent/IL191911D0/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39133667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL191911(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of IL191911A publication Critical patent/IL191911A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38—Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412—Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
IL191911A 2005-12-13 2008-06-03 Immunogenic composition comprising s. pneumoniae capsular saccharide conjugates and various aspects related thereto IL191911A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GB0526232A GB0526232D0 (en) 2005-12-22 2005-12-22 Vaccine
GBGB0607088.2A GB0607088D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0607087A GB0607087D0 (en) 2006-04-07 2006-04-07 Vaccine
GB0609902A GB0609902D0 (en) 2006-05-18 2006-05-18 Novel composition
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
PCT/GB2006/004634 WO2007068907A2 (en) 2005-12-13 2006-12-12 Vaccine compositions comprising a saponin adjuvant
PCT/EP2006/069977 WO2007071710A2 (en) 2005-12-22 2006-12-20 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates

Publications (2)

Publication Number Publication Date
IL191911D0 true IL191911D0 (en) 2008-12-29
IL191911A IL191911A (en) 2015-09-24

Family

ID=39133667

Family Applications (5)

Application Number Title Priority Date Filing Date
IL19191308A IL191913A (en) 2005-12-13 2008-06-03 Streptococcus pneumoniae immunogenic composition comprising s. pneumoniae capsular saccharides conjugated to carrier proteins and its use in the manufacture of a medicament for treating diseases caused by s. pneumoniae infection
IL191911A IL191911A (en) 2005-12-13 2008-06-03 Immunogenic composition comprising s. pneumoniae capsular saccharide conjugates and various aspects related thereto
IL19208408A IL192084A (en) 2005-12-13 2008-06-12 Immunogenic composition for infants comprising a multivalent streptococcus pneumoniae vaccine and its use
IL21166411A IL211664D0 (en) 2005-12-13 2011-03-10 Streptococcus pnevmoniae immunogenic
IL219641A IL219641A (en) 2005-12-13 2012-05-08 Immunogenic composition comprising at least four s.pneumoniae capsular saccharide conjugates containing saccharides from different s.pneumoniae serotypes and various aspects related thereto

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL19191308A IL191913A (en) 2005-12-13 2008-06-03 Streptococcus pneumoniae immunogenic composition comprising s. pneumoniae capsular saccharides conjugated to carrier proteins and its use in the manufacture of a medicament for treating diseases caused by s. pneumoniae infection

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL19208408A IL192084A (en) 2005-12-13 2008-06-12 Immunogenic composition for infants comprising a multivalent streptococcus pneumoniae vaccine and its use
IL21166411A IL211664D0 (en) 2005-12-13 2011-03-10 Streptococcus pnevmoniae immunogenic
IL219641A IL219641A (en) 2005-12-13 2012-05-08 Immunogenic composition comprising at least four s.pneumoniae capsular saccharide conjugates containing saccharides from different s.pneumoniae serotypes and various aspects related thereto

Country Status (37)

Country Link
US (9) US20090017072A1 (en)
EP (10) EP3130348A1 (en)
JP (7) JP5461838B2 (en)
KR (4) KR101367237B1 (en)
CN (6) CN101378778B (en)
AR (3) AR058592A1 (en)
AT (1) AT520415T (en)
AU (4) AU2006327040B2 (en)
BR (3) BRPI0620460B1 (en)
CA (5) CA2808919C (en)
CL (1) CL2013002106A1 (en)
CR (2) CR10119A (en)
CY (4) CY1112677T1 (en)
DK (5) DK3017827T3 (en)
EA (3) EA014165B1 (en)
ES (4) ES2539795T3 (en)
HK (1) HK1120230A1 (en)
HR (4) HRP20110685T1 (en)
HU (3) HUE032903T2 (en)
IL (5) IL191913A (en)
JO (1) JO2813B1 (en)
LT (3) LT1973564T (en)
MA (3) MA30062B1 (en)
MX (2) MX354843B (en)
MY (4) MY150719A (en)
NO (3) NO344187B1 (en)
NZ (4) NZ569077A (en)
PE (2) PE20071305A1 (en)
PH (1) PH12014502544A1 (en)
PL (4) PL1962899T3 (en)
PT (5) PT2384765T (en)
SG (1) SG168517A1 (en)
SI (5) SI1968631T1 (en)
TR (1) TR201900418T4 (en)
TW (4) TWI415622B (en)
UA (2) UA96583C2 (en)
WO (3) WO2007071710A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ304795B6 (en) * 2000-06-29 2014-10-29 Glaxosmithkline Biologicals S. A. Multivalent immunogenic composition
ES2258108T3 (en) * 2000-11-07 2006-08-16 Immunovaccine Technologies Inc. Vaccines with improved immune response and same preparation procedures.
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9789179B2 (en) * 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
TWI415622B (en) * 2005-12-22 2013-11-21 Glaxosmithkline Biolog Sa Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof
JP5081243B2 (en) * 2006-08-17 2012-11-28 ザ ユーエービー リサーチ ファウンデーション Method of using pneumococcal antigen as an index of pneumococcal pneumonia in a subject
US8398985B2 (en) * 2007-04-23 2013-03-19 Serum Institute Of India Ltd. Antigenic polysaccharides and process for their preparation
CA2685506A1 (en) * 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
AU2008267208B2 (en) * 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US9498493B2 (en) 2007-09-27 2016-11-22 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
ES2383231T3 (en) 2007-10-19 2012-06-19 Novartis Ag Formulations for meningococcal vaccines
US8226959B2 (en) 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
WO2009127677A1 (en) * 2008-04-16 2009-10-22 Glaxosmithkline Biologicals S.A. Vaccine
US20120164178A1 (en) * 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
WO2009143413A1 (en) * 2008-05-22 2009-11-26 Children'smedical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BRPI0923006A2 (en) 2008-12-17 2016-03-08 Novartis Ag meningococcal vaccines including hemoglobin receptor
US20120064104A1 (en) * 2009-03-24 2012-03-15 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
AU2010227220B2 (en) * 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
WO2010109323A1 (en) 2009-03-24 2010-09-30 Novartis Ag Adjuvanting meningococcal factor h binding protein
BRPI1014494A2 (en) * 2009-04-30 2016-08-02 Coley Pharm Group Inc pneumococcal vaccine and its uses
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
SG178904A1 (en) 2009-09-10 2012-04-27 Novartis Ag Combination vaccines against respiratory tract diseases
KR20110068831A (en) * 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 A liposomal composition, a process for the preparation thereof, and a use thereof as a pneumococcal vaccine
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CN103533954B (en) 2011-03-02 2015-09-09 诺华股份有限公司 Combination vaccine containing a low dose of antigens and / or adjuvants
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
US20140072622A1 (en) * 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
SG11201401177WA (en) 2011-10-06 2014-04-28 Immunovaccine Technologies Inc Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
HUE040914T4 (en) * 2012-01-30 2019-05-28 Serum Institute Of India Private Ltd Immunogenic composition
CN104114706A (en) 2012-02-02 2014-10-22 诺华股份有限公司 Promoters for increased protein expression in meningococcus
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
WO2013132043A1 (en) 2012-03-08 2013-09-12 Novartis Ag Combination vaccines with tlr4 agonists
KR20130142574A (en) 2012-06-20 2013-12-30 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
RU2510281C2 (en) * 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") HYBRID PROTEIN VACCINE AGAINST PNEUMONIA CAUSED BY Streptococcus pneumoniae
WO2014009971A2 (en) * 2012-07-07 2014-01-16 Bharat Biotech International Limited Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
MX363511B (en) * 2012-08-16 2019-03-26 Pfizer Glycoconjugation processes and compositions.
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
KR20140075196A (en) 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20140075201A (en) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 Multivalent pneumococcal polysaccharide-protein conjugate composition
CN105007935A (en) 2012-12-18 2015-10-28 葛兰素史密丝克莱恩生物有限公司 Conjugates for protecting against diphtheria and/or tetanus
RU2544168C1 (en) * 2014-01-17 2015-03-10 Андрей Дмитриевич Протасов Method for forming immunological memory to streptococcus pneumoniae antigens in patients with chronic obstructive pulmonary disease
WO2015110942A2 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
AU2015208821B2 (en) * 2014-01-21 2017-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JP2017505792A (en) * 2014-02-14 2017-02-23 ファイザー・インク Immunogenic glycoprotein conjugates
CN103893751B (en) * 2014-03-26 2016-04-20 天津康希诺生物技术有限公司 Pneumococcal polysaccharide-protein conjugate vaccine and its preparation method
CN103936842B (en) * 2014-04-30 2016-03-23 重庆医科大学 Application of pneumolysin mutants and their use as a mucosal immunoadjuvant
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2600838C1 (en) * 2015-06-08 2016-10-27 Андрей Дмитриевич Протасов Method of enhancing nonspecific protection factors activity in patients with chronic obstructive pulmonary disease
KR20160146240A (en) 2015-06-12 2016-12-21 전관구 Manufacturing process of silver oxide nanoparticle and silver nanoparticle
JP2018524380A (en) * 2015-07-21 2018-08-30 ファイザー・インク Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising them and their use
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
JP2019526620A (en) * 2016-08-05 2019-09-19 サノフィ パスツール インコーポレイティッド Polyvalent pneumococcal polysaccharide-protein conjugate composition
BR112019006278A2 (en) 2016-09-30 2019-07-02 Biological E Ltd multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
KR20180046893A (en) * 2016-10-28 2018-05-09 주식회사 엘지화학 A multivalent immunogenic composition with improved IgG titer and use thereof
CN108144052A (en) * 2016-12-02 2018-06-12 武汉博沃生物科技有限公司 Streptococcus pneumoniae polysaccharides-protein conjugate and its preparation method and purposes
WO2018134693A1 (en) * 2017-01-20 2018-07-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
KR20190111952A (en) * 2017-01-31 2019-10-02 머크 샤프 앤드 돔 코포레이션 Method for producing capsular polysaccharide protein conjugate derived from Streptococcus pneumoniae serotype 19F
WO2018144799A1 (en) * 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN107929728A (en) * 2017-04-19 2018-04-20 武汉博沃生物科技有限公司 A kind of pneumoprotein vaccine and preparation method thereof
WO2019043245A1 (en) * 2017-09-04 2019-03-07 London School Of Hygiene And Tropical Medicine Microbial cells expressing streptococcal serotypes
WO2019050818A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
CN108524926A (en) * 2018-06-29 2018-09-14 康希诺生物股份公司 A kind of formulation compositions of multivalent pneumococcal combined vaccine and its application

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
BE889979A (en) 1981-08-14 1982-02-15 Smith Kline Rit polysaccharide preparation Method bacterial capsular antigenic purified, obtained products and their use
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4619828A (en) 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein Immunogenic membrane protein complex, seen for the front up and tell priority over derav as immune stimulant and as vaccine
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa Glycoprotein conjugate to attivita 'trivalent immunogenic
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
AU614755B2 (en) 1987-06-05 1991-09-12 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Autocrine motility factors in cancer diagnosis and management
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag Synthetic antigenic, process for their production and their use
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AT115862T (en) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocols as a vaccine adjuvant.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa Vaccines and fluids active principles of vectors containing a metabolizable oil
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa injecting multiphase emulsions
US5334379A (en) 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use for the development of synthetic vaccines.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren Protein D - an IgD-binding protein FROM Haemophilus influenzae, and anvaendning this Foer analysis, vaccines and uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AT128628T (en) 1990-08-13 1995-10-15 American Cyanamid Co Fiber hemagglutinin of Bordetella pertussis as carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
ES2118812T3 (en) 1991-02-15 1998-10-01 Uab Research Foundation Pneumococcal protein structural gene.
GB9105992D0 (en) 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
KR950700081A (en) 1992-02-11 1995-01-16 W 로우 죤 Dual carrier immunogenic composition
IT1262896B (en) 1992-03-06 1996-07-22 Compounds conjugates formed by heat shock proteins (hsp) poly- and oligo-saccharides, their use for the production of vaccines.
MA22842A1 (en) 1992-03-27 1993-10-01 Smithkline Beecham Biolog Process for the preparation of vaccine compositions.
AU4230493A (en) 1992-05-06 1993-11-29 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
AT188508T (en) 1992-06-18 2000-01-15 Harvard College Vaccines against diphtheria toxin
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
GB9224584D0 (en) 1992-11-23 1993-01-13 Connaught Lab Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
JP4028593B2 (en) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニムＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｂｉｏｌｏｇｉｃａｌｓ Ｓ．Ａ． 3-O deacylated monophosphoryl lipid A-containing vaccine composition
DE69431624T2 (en) 1993-05-18 2003-07-10 Univ Ohio State Res Found Vaccine against middle ear inflammation
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
SI0729473T1 (en) 1993-11-17 2001-02-28 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
CA2217178C (en) 1995-04-25 2009-09-29 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
AT323721T (en) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-binding protein used as a pneumokoken-targeted vaccine
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
AT234129T (en) 1996-06-18 2003-03-15 Alza Corp Apparatus for improving transdermal administration of medicaments or the acceptance of body fluids
EP0956289A4 (en) 1996-08-16 2004-10-13 Smithkline Beecham Corp Novel prokaryotic polynucleotides, polypeptides and their uses
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US6420135B1 (en) 1996-10-31 2002-07-16 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CA2269636A1 (en) 1996-11-12 1998-05-22 The Regents Of The University Of Minnesota C3 binding protein of streptococcus pneumoniae
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DK0957972T3 (en) 1996-12-20 2003-07-21 Alza Corp A device and method for increasing the transdermal average flux
DE19708537A1 (en) 1997-03-03 1998-09-10 Biotechnolog Forschung Gmbh Novel surface protein (SpsA protein) of Streptococcus pneumoniae etc.
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
FR2763244B1 (en) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc multivalent vaccine composition is mixed carrier
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
EP1000144B1 (en) 1997-06-03 2007-12-12 Sanofi Pasteur Limited Lactoferrin receptor gene of moraxella
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1017828A1 (en) 1997-09-24 2000-07-12 American Cyanamid Company HUMAN COMPLEMENT C3-DEGRADING PROTEINASE FROM $i(STREPTOCOCCUS PNEUMONIAE)
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L A device for controlling the depth 'of penetration of a needle, in particular applicable to a syringe for injections
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
AU764811B2 (en) 1998-04-07 2003-08-28 Medimmune, Llc A polypeptide comprising the amino acid of an n-terminal choline binding protein A truncate, vaccine derived therefrom and uses thereof
CA2325340A1 (en) 1998-04-07 1999-10-14 Medimmune, Inc. Derivatives of pneumococcal choline binding proteins for vaccines
EP1073450A4 (en) 1998-04-23 2003-04-23 Uab Research Foundation PNEUMOCOCCAL SURFACE PROTEIN C(PspC), EPITOPIC REGIONS AND STRAIN SELECTION THEREOF, AND USES THEREFOR
HU0102332A3 (en) 1998-06-08 2002-11-28 Sca Emballage France Fast flattening packaging
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
HU0102475A3 (en) 1998-06-30 2001-12-28 Om Pharma Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same
AT446107T (en) 1998-08-19 2009-11-15 Baxter Healthcare Sa Immunogenous beta-propionamido-bound polysaccharid protein conjugate is suitable for vaccination and manufacturing of n-acrylylated polysaccharide
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
AU6060899A (en) 1998-09-24 2000-04-10 American Cyanamid Company Human complement c3-degrading polypeptide from (streptococcus pneumoniae)
US6541616B1 (en) 1998-10-01 2003-04-01 Antex Biologics Inc. Moraxella catarrhalis protein, gene sequence and uses thereof
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
GB2359228A (en) 1998-11-17 2001-08-15 Schlumberger Technology Corp Transmitting information over a communication link
WO2000029434A2 (en) 1998-11-19 2000-05-25 St. Jude Children's Research Hospital PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
EP2050464B1 (en) 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
EA007409B1 (en) 1998-12-23 2006-10-27 Шайе Биокем Инк. Antigenic polypeptides streptococci, methods for their preparation and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Ingileif Jonsdottir Intranasal delivery of pneumococcal polysaccharide vaccines
BRPI0009163B1 (en) 1999-03-19 2019-04-09 Smithkline Beecham Biologicals S.A. Immunogenic composition and vaccine comprising it
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin a protein carrier for the polysaccharide conjugate vaccine
AU764969B2 (en) 1999-04-19 2003-09-04 Smithkline Beecham Biologicals (Sa) Vaccines
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU777856B2 (en) 1999-06-10 2004-11-04 Human Genome Sciences, Inc. Streptococcus pneumoniae proteins and vaccines
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
FR2806304B1 (en) * 2000-03-17 2002-05-10 Aventis Pasteur polysaccharide conjugate pneumococcal vaccine use has against tetanus and diphtheria
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
KR100927767B1 (en) 2000-06-20 2009-11-20 아이디 바이오메디칼 코포레이션 Streptococcus antigens
CZ304795B6 (en) * 2000-06-29 2014-10-29 Glaxosmithkline Biologicals S. A. Multivalent immunogenic composition
JP4843181B2 (en) 2000-08-04 2011-12-21 コリクサ コーポレイション Immune effector compounds
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1322656B1 (en) 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
WO2002078673A1 (en) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Process for producing fine granulate drug
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
FR2827199B1 (en) 2001-07-10 2004-07-09 Centre Nat Rech Scient Method and ex situ production machine networks of low and medium integration biochips
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
CA2474398A1 (en) 2002-02-04 2003-08-14 Corixa Corporation New immunoeffector compounds
WO2004011027A1 (en) 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
AU2003250204B8 (en) 2002-08-02 2008-07-10 Glaxosmithkline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
NZ541969A (en) 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
KR20060084789A (en) 2003-06-23 2006-07-25 박스터 헬쓰케어 에스.에이. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
JP5174457B2 (en) 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト Neisseria meningitidis lgtBLOS as an adjuvant
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
TWI386222B (en) 2005-04-08 2013-02-21 Wyeth Corp Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
EP1945249A2 (en) 2005-11-01 2008-07-23 Novartis AG Compositions with antigens adsorbed to calcium phosphate
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
TWI415622B (en) 2005-12-22 2013-11-21 Glaxosmithkline Biolog Sa Streptococcus pneumoniae immunogenic composition comprising capsular saccharide conjugates, vaccine and kit comprising the same and uses thereof
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2008267208B2 (en) 2007-06-26 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
MX346071B (en) 2008-12-18 2017-03-02 Wyeth Llc Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon.

Also Published As

Publication number Publication date
US20180207262A1 (en) 2018-07-26
EP3020411A1 (en) 2016-05-18
EA200801344A1 (en) 2008-12-30
JP2009520760A (en) 2009-05-28
CN110179974A (en) 2019-08-30
CY1118535T1 (en) 2017-07-12
NZ569076A (en) 2011-08-26
EP3470080A1 (en) 2019-04-17
US20150190521A1 (en) 2015-07-09
SI3017827T1 (en) 2019-01-31
SG168517A1 (en) 2011-02-28
UA96934C2 (en) 2011-12-26
PT2384765T (en) 2017-02-06
EP2384765A3 (en) 2012-06-20
JP5849125B2 (en) 2016-01-27
MA30065B1 (en) 2008-12-01
HUE032903T2 (en) 2017-11-28
JP5579387B2 (en) 2014-08-27
NO20082647L (en) 2008-09-18
MY148141A (en) 2013-03-15
UA96583C2 (en) 2011-11-25
WO2007071710A2 (en) 2007-06-28
CA2634885A1 (en) 2007-06-28
JP5792920B2 (en) 2015-10-14
EA014107B1 (en) 2010-10-29
PT1973564T (en) 2017-01-24
AU2010241281B2 (en) 2012-12-06
EP1968631A2 (en) 2008-09-17
EP3130348A1 (en) 2017-02-15
CA2808919A1 (en) 2007-06-28
KR20140036327A (en) 2014-03-25
PE20071058A1 (en) 2007-11-27
WO2007071710A3 (en) 2007-11-29
TWI465248B (en) 2014-12-21
NZ569077A (en) 2011-08-26
US10279033B2 (en) 2019-05-07
TW201350129A (en) 2013-12-16
IL219641D0 (en) 2012-06-28
MA30066B1 (en) 2008-12-01
IL191913A (en) 2012-07-31
BRPI0620163A2 (en) 2011-11-01
IL192084D0 (en) 2008-12-29
NO344187B1 (en) 2019-09-30
CA2634887A1 (en) 2007-06-28
WO2007071707A3 (en) 2007-09-13
CY1112677T1 (en) 2016-02-10
CY1118345T1 (en) 2017-06-28
IL211664D0 (en) 2011-05-31
CN103585623B (en) 2016-09-28
KR20080081061A (en) 2008-09-05
TW200738258A (en) 2007-10-16
WO2007071711A2 (en) 2007-06-28
JP5600337B2 (en) 2014-10-01
DK1973564T3 (en) 2017-01-16
DK3017827T3 (en) 2019-02-18
KR20130103831A (en) 2013-09-24
EP1968631B1 (en) 2015-04-08
HRP20161681T1 (en) 2017-01-13
EA200801367A1 (en) 2008-12-30
CN101374548A (en) 2009-02-25
CN101378778A (en) 2009-03-04
EP3017827B1 (en) 2018-11-07
JP5749689B2 (en) 2015-07-15
CL2013002106A1 (en) 2014-03-07
HRP20161682T1 (en) 2017-01-27
PL2384765T3 (en) 2017-05-31
MX2008008140A (en) 2008-09-24
AU2010241281A1 (en) 2010-11-25
NZ569168A (en) 2012-02-24
CN101378779B (en) 2015-09-02
SI2384765T1 (en) 2017-03-31
PT1962899E (en) 2011-10-19
EP2384765A2 (en) 2011-11-09
ES2707499T3 (en) 2019-04-03
KR101441368B1 (en) 2014-09-24
SI1962899T1 (en) 2011-11-30
CY1116407T1 (en) 2017-02-08
JP2014205673A (en) 2014-10-30
BRPI0620193A2 (en) 2011-11-01
US20190262447A1 (en) 2019-08-29
LT1973564T (en) 2016-12-27
AU2006327036B2 (en) 2012-11-15
HK1120230A1 (en) 2011-12-09
NZ596500A (en) 2013-05-31
EP1962899B1 (en) 2011-08-17
EP3017827A1 (en) 2016-05-11
CR10122A (en) 2008-08-21
LT3017827T (en) 2019-01-10
CA2808919C (en) 2016-04-19
CA2633772C (en) 2015-09-15
CN101378778B (en) 2013-02-06
US20160243219A1 (en) 2016-08-25
US20090017072A1 (en) 2009-01-15
HRP20110685T1 (en) 2011-10-31
CA2634885C (en) 2016-04-19
CN101378779A (en) 2009-03-04
DK2384765T3 (en) 2017-01-09
JP2012232985A (en) 2012-11-29
TR201900418T4 (en) 2019-02-21
BRPI0620460B1 (en) 2019-08-13
MX354843B (en) 2018-03-22
EP2402025A3 (en) 2012-03-07
SI1968631T1 (en) 2015-07-31
US20150265702A1 (en) 2015-09-24
KR20080081063A (en) 2008-09-05
DK1962899T3 (en) 2011-10-31
US9107872B2 (en) 2015-08-18
US20090017059A1 (en) 2009-01-15
AU2006327040B2 (en) 2010-08-19
MY150719A (en) 2014-02-28
ES2614938T3 (en) 2017-06-02
TW200738257A (en) 2007-10-16
PL3017827T3 (en) 2019-04-30
BRPI0620460A2 (en) 2011-11-16
JP2009520761A (en) 2009-05-28
CR10119A (en) 2008-07-29
MY160199A (en) 2017-02-28
JP2009520759A (en) 2009-05-28
CN103251940A (en) 2013-08-21
WO2007071707A2 (en) 2007-06-28
CA2816182A1 (en) 2007-06-28
IL191913D0 (en) 2009-02-11
KR101418240B1 (en) 2014-07-16
PT1968631E (en) 2015-07-20
JP2012211165A (en) 2012-11-01
KR101367237B1 (en) 2014-03-14
IL192084A (en) 2013-11-28
AR058707A1 (en) 2008-02-20
MA30062B1 (en) 2008-12-01
CN101374548B (en) 2013-05-01
WO2007071710A8 (en) 2008-09-04
BRPI0620163B1 (en) 2019-08-13
HUE033081T2 (en) 2017-11-28
LT2384765T (en) 2017-01-10
ES2539795T3 (en) 2015-07-06
EP2402025A2 (en) 2012-01-04
JO2813B1 (en) 2014-09-15
AT520415T (en) 2011-09-15
EP1973564B1 (en) 2016-11-09
DK1968631T3 (en) 2015-06-15
KR20080081060A (en) 2008-09-05
HRP20190037T1 (en) 2019-02-22
PE20071305A1 (en) 2007-12-14
NO20082646L (en) 2008-09-16
US20090010959A1 (en) 2009-01-08
JP5615323B2 (en) 2014-10-29
WO2007071711A3 (en) 2007-11-08
ES2630759T3 (en) 2017-08-23
EP2384765B1 (en) 2016-11-23
NO343981B1 (en) 2019-08-05
IL219641A (en) 2017-10-31
KR101365001B1 (en) 2014-02-21
EP1962899A2 (en) 2008-09-03
IL191911A (en) 2015-09-24
TWI487534B (en) 2015-06-11
AR058706A1 (en) 2008-02-20
AU2006327036A1 (en) 2007-06-28
JP5461838B2 (en) 2014-04-02
EA014165B1 (en) 2010-10-29
US20100074922A1 (en) 2010-03-25
EP1973564A2 (en) 2008-10-01
CA2816182C (en) 2018-02-20
EP2382986A3 (en) 2012-08-22
PH12014502544A1 (en) 2015-12-14
AU2006327041A1 (en) 2007-06-28
PL1962899T3 (en) 2011-12-30
MY147495A (en) 2012-12-14
US9884113B2 (en) 2018-02-06
PL1973564T3 (en) 2017-04-28
CA2633772A1 (en) 2007-06-28
EA014649B1 (en) 2010-12-30
JP2012229228A (en) 2012-11-22
US20180250389A9 (en) 2018-09-06
SI1973564T1 (en) 2017-02-28
AU2006327041B2 (en) 2010-08-26
CA2634887C (en) 2016-01-19
AU2006327040A1 (en) 2007-06-28
PT3017827T (en) 2019-01-28
TWI415622B (en) 2013-11-21
AR058592A1 (en) 2008-02-13
EP2382986A2 (en) 2011-11-02
HUE041979T2 (en) 2019-06-28
CN103585623A (en) 2014-02-19
NO20082718L (en) 2008-09-16
EA200801374A1 (en) 2008-12-30

Similar Documents

Publication Publication Date Title
DK1968631T3 (en) Vaccine
DK2417983T3 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
GB2427355B (en) Combination mattress
GB2423943B (en) Toys
AP2436A (en) Immunogenic composition
DK1912671T3 (en) BETA-glucuronide-LINKER-drug conjugates
EP1942105A4 (en) Aminodihydrothiazine derivative
HK1084958A1 (en) S. pneumoniae antigens
DK2074221T3 (en) Improved methods for separating Streptococcus pneumoniae type 3 polysaccharides
IL197310D0 (en) Vaccine
DK1868645T3 (en) Multivalent pneumococcal saccharide-protein conjugate composition
PT1968630T (en) Multivalent pcv2 immunogenic compositions
ZA200802051B (en) Anti-CD3 antibody formulations
HK1121054A1 (en) Molecular conjugate
AT492290T (en) SACCHARIDE conjugate vaccines
EP1773878A4 (en) Insulin-oligomer conjugates, formulations and uses thereof
IL220816A (en) Process for preparing cell-binding agent-cytotoxic agent conjugates
HK1116697A1 (en) Psma antibody-drug conjugates psma
HK1215189A1 (en) Multivalent pneumococcal polysaccharide protein conjugate composition
PL378012A1 (en) Anthracycline-antibody conjugates
GB0411411D0 (en) Vaccines
PT1957647E (en) Immunostimulatory oligoribonucleotides
EP1994057A4 (en) Camptothecin-binding moiety conjugates
ME01965B (en) Stabilizers for freeze-dried vaccines
PL1861572T3 (en) Furniture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed